Your browser is no longer supported. Please, upgrade your browser.
ZYNE Zynerba Pharmaceuticals, Inc. daily Stock Chart
ZYNE [NASD]
Zynerba Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.27 Insider Own0.90% Shs Outstand21.31M Perf Week-3.20%
Market Cap276.82M Forward P/E- EPS next Y-1.66 Insider Trans0.00% Shs Float18.17M Perf Month-3.99%
Income-36.80M PEG- EPS next Q-0.50 Inst Own12.80% Short Float16.98% Perf Quarter127.10%
Sales0.09M P/S3218.80 EPS this Y-5.20% Inst Trans-13.07% Short Ratio1.14 Perf Half Y304.67%
Book/sh3.50 P/B3.71 EPS next Y18.30% ROA-54.90% Target Price21.75 Perf Year4.84%
Cash/sh3.21 P/C4.05 EPS next 5Y- ROE-64.10% 52W Range2.75 - 16.47 Perf YTD337.37%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-21.13% Beta4.83
Dividend %- Quick Ratio9.90 Sales past 5Y- Gross Margin- 52W Low372.36% ATR1.15
Employees25 Current Ratio9.90 Sales Q/Q- Oper. Margin- RSI (14)52.24 Volatility6.90% 9.59%
OptionableYes Debt/Eq0.00 EPS Q/Q48.50% Profit Margin- Rel Volume0.28 Prev Close13.34
ShortableYes LT Debt/Eq0.00 EarningsJun 10 BMO Payout- Avg Volume2.71M Price12.99
Recom1.80 SMA203.19% SMA507.86% SMA20080.31% Volume754,118 Change-2.62%
Apr-22-19Resumed Canaccord Genuity Buy
Feb-01-18Resumed H.C. Wainwright Buy $23
Jan-29-18Initiated Ladenburg Thalmann Buy $25.50
Jan-26-18Initiated Seaport Global Securities Buy $16
Oct-02-17Upgrade Cantor Fitzgerald Neutral → Overweight $4 → $17
Sep-29-17Upgrade Piper Jaffray Neutral → Overweight
Aug-15-17Upgrade ROTH Capital Neutral → Buy
Aug-15-17Downgrade Oppenheimer Outperform → Perform
Aug-15-17Downgrade Jefferies Buy → Hold
Aug-08-17Downgrade ROTH Capital Buy → Neutral
Aug-08-17Downgrade H.C. Wainwright Buy → Neutral $7
Aug-07-17Downgrade Piper Jaffray Overweight → Neutral
Aug-07-17Downgrade Maxim Group Buy → Hold
Aug-07-17Downgrade Cantor Fitzgerald Overweight → Neutral $28 → $4
Mar-28-17Reiterated H.C. Wainwright Buy $22 → $30
Feb-24-17Initiated Maxim Group Buy $32
Dec-22-16Initiated Cantor Fitzgerald Overweight $28
Dec-06-16Resumed Jefferies Buy
Oct-07-16Initiated H.C. Wainwright Buy $22
Nov-12-15Reiterated Oppenheimer Outperform $40 → $34
Jun-20-19 09:15AM  Fed Statement Keeps Rally Alive Zacks
Jun-19-19 05:45PM  Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know Zacks
Jun-13-19 07:04PM  Understanding Medical Cannabis vs. Recreational Cannabis Stocks Investopedia
03:11PM  MediaJel Acquires Potnt Agency, Adds Merida Capital's Thomas Harrison As Chairman Benzinga
Jun-12-19 05:45PM  Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know Zacks
09:39AM  Zynerba Up on Second Patent for Cannabidiol Candidate in 2019 Zacks
Jun-11-19 12:00PM  Why Zynerba Pharmaceuticals Stock Is Skyrocketing Today Motley Fool +16.58%
11:26AM  Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder InvestorPlace
08:22AM  Zynerba Advances Cannabidiol Treatment With New Patent Win Benzinga
07:00AM  Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol GlobeNewswire
Jun-10-19 12:43PM  Top Marijuana Stocks on the NASDAQ Investopedia
Jun-04-19 06:00AM  Here's What Last Week's FDA CBD Hearing Really Means for Cannabis Stocks Motley Fool +12.72%
May-31-19 09:40AM  Zynerba Initiates Phase II INSPIRE Trial Of Zygel Market Exclusive
May-30-19 04:30PM  Zynerba Pharmaceuticals to Present at FDAs Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-derived Compounds GlobeNewswire
May-29-19 06:45AM  Zynerba Pharmaceuticals Announces Initiation of Phase 2 Trial of Zygel in 22q11.2 Deletion Syndrome GlobeNewswire +7.04%
May-28-19 11:30AM  Zynerba Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference GlobeNewswire -8.35%
10:43AM  3 Strong Buy Cannabis Biotech Stocks To Know Now TipRanks
May-24-19 09:30AM  Is Zynerba Pharmaceuticals (ZYNE) Outperforming Other Medical Stocks This Year? Zacks
08:32AM  UC Davis researcher looks to cannabis compound to treat developmental disorders American City Business Journals
May-23-19 08:41AM  Options Traders Expect Huge Moves in Zynerba Pharmaceuticals (ZYNE) Stock Zacks -7.71%
May-21-19 08:07AM  Zynerba Pharmaceuticals, Inc. (ZYNE) Shares March Higher, Can It Continue? Zacks
May-10-19 02:16PM  Can We See Significant Insider Ownership On The Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Share Register? Simply Wall St. +6.69%
May-08-19 09:30AM  Is Zynerba Pharmaceuticals (ZYNE) Outperforming Other Medical Stocks This Year? Zacks
06:58AM  Zynerba: 1Q Earnings Snapshot Associated Press
06:50AM  Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights GlobeNewswire
May-06-19 04:20PM  Why Zynerba Pharmaceuticals Stock Zoomed Higher Today Motley Fool +11.44%
12:14PM  Zynerba stock soars after getting 'fast track' designation for experimental cannibanoid therapy American City Business Journals
07:00AM  Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS) GlobeNewswire
Apr-30-19 11:56AM  Why Zynerba Pharmaceuticals Stock Is Jumping Today Motley Fool +8.30%
10:02AM  What's in the Cards for Zynerba (ZYNE) This Earnings Season? Zacks
Apr-24-19 05:45PM  Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know Zacks
Apr-18-19 09:30AM  Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year? Zacks
Apr-17-19 05:45PM  Zynerba Pharmaceuticals (ZYNE) Dips More Than Broader Markets: What You Should Know Zacks
Apr-16-19 12:28PM  5 Marijuana Stocks Wall Street Is Most Bullish On Kiplinger
Apr-15-19 05:55AM  Will Zynerba Pharmaceuticals Continue to Surge Higher? Zacks
Apr-11-19 02:35PM  These Four Marijuana Stocks Could Make Moves On Thursday ACCESSWIRE +8.15%
Apr-05-19 08:50AM  Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock? Zacks +13.08%
Apr-02-19 03:52PM  Ladenburg Bullish on Zynerba (ZYNE) Stock as FDA Clarifies Its Views on Availability of Non-Prescription CBD SmarterAnalyst +20.00%
10:00AM  Zynerba Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-22-19 01:00PM  Cannabis Breakout Candidates - THC Therapeutics, Inc. (THCT) ACCESSWIRE -6.02%
09:27AM  Will Zynerba Pharmaceuticals Continue to Surge Higher? Zacks
Mar-20-19 01:45PM  These Four Marijuana Stocks Are Bringing The Heat On Wednesday ACCESSWIRE +11.67%
Mar-18-19 03:36PM  These 3 Cannabis Stocks Are Set to Skyrocket, Say Analysts SmarterAnalyst
Mar-14-19 04:39PM  SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update PR Newswire
Mar-11-19 06:58AM  Zynerba: 4Q Earnings Snapshot Associated Press
06:50AM  Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational Highlights GlobeNewswire
Mar-07-19 07:00AM  Zynerba Pharmaceuticals Initiates Phase 2 Trial of Zygel in Autism Spectrum Disorder GlobeNewswire
Mar-01-19 12:35PM  Does Zynerba Pharmaceuticals, Inc.s (NASDAQ:ZYNE) CEO Pay Reflect Performance? Simply Wall St.
Feb-26-19 10:21AM  Zynerba's Patent Win Sends Cannabis Biotech's Shares Higher Benzinga
09:45AM  These Four Healthcare Stocks Are Heating Up On Tuesday ACCESSWIRE
07:00AM  Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Cannabidiol GlobeNewswire
Feb-21-19 01:26PM  Zynerba Pharmaceuticals Receives International Patent For Osteoarthritis Treatment With CBD Gel Benzinga +5.71%
Feb-20-19 07:00AM  Zynerba Pharmaceuticals Appoints Pamela Stephenson to Board of Directors GlobeNewswire
Feb-13-19 11:45AM  Healthcare Investment Opportunities You Can't Miss ACCESSWIRE
Feb-11-19 09:55AM  Biotech Stocks To Watch ACCESSWIRE
Feb-08-19 09:30AM  Has Zynerba Pharmaceuticals (ZYNE) Outpaced Other Medical Stocks This Year? Zacks
Feb-07-19 11:44AM  Zynerba Stock Is Marijuana-Adjacent Play Worth a Look InvestorPlace
Feb-05-19 10:00AM  Zynerba Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference GlobeNewswire -6.69%
Feb-04-19 03:41PM  Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q3 Zacks +5.87%
11:00AM  Cannabis & Biotech Stocks Starting to Rally in 2019 ACCESSWIRE
Feb-01-19 08:30AM  Biotechs to Put on Your Watchlist ACCESSWIRE +10.50%
Jan-30-19 08:00AM  Today's Research Reports on Trending Tickers: BioTime and Zynerba Pharmaceuticals ACCESSWIRE
08:00AM  Biotechs You Need to Radar Now ACCESSWIRE
Jan-29-19 02:30PM  These 4 Healthcare Stocks Healthy With Potential Opportunities ACCESSWIRE +25.26%
12:56PM  Zynerba Pharmaceuticals News: Why ZYNE Stock Is Soaring Today InvestorPlace
08:30AM  Wall Street's Favorite Cannabis Stock Benzinga
Jan-22-19 08:45AM  SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors PR Newswire
Jan-07-19 09:00AM  Options Traders Expect Huge Moves in Zynerba Pharmaceuticals (ZYNE) Stock Zacks
Jan-04-19 05:11PM  Which Biopharma Stocks Are Looking To Score Big In Cannabis Medicine? Investor's Business Daily +8.99%
Dec-19-18 09:15AM  Zynerba Gives Clinical Update, Lifelong Impact Of ZYN002 Market Exclusive
Dec-13-18 07:56AM  The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen Benzinga -7.23%
Dec-12-18 05:30PM  Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002 GlobeNewswire
06:31AM  When Will Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Become Profitable? Simply Wall St.
Nov-23-18 07:40AM  Detailed Research: Economic Perspectives on Wingstop, Marlin Business Services, Aware, Zynerba Pharmaceuticals, Auris Medical Holding AG, and Gulf Island Fabrication What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-21-18 11:30AM  Opioid Alternatives Could Make Investors Major Gains ACCESSWIRE
Nov-20-18 08:00AM  Zynerba Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-13-18 02:19PM  Sell-Side Analysts See Upside Potential In Zynerba Benzinga -5.12%
Nov-08-18 10:00AM  Zynerba: 3Q Earnings Snapshot Associated Press +6.15%
06:45AM  Zynerba Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights GlobeNewswire
Nov-01-18 10:30AM  Reading Filings to Predict Future Events ACCESSWIRE +9.89%
Oct-26-18 02:00PM  Short Sellers Are Making Huge Profits In Cannabis Stocks Benzinga
Oct-23-18 10:09AM  Medical Cannabis Stocks Vs. Recreational Cannabis Stocks: Which Ones Should You Invest In? Investopedia
Oct-22-18 08:37AM  Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options Zacks -7.66%
Oct-11-18 10:47AM  Zynerba Pharmaceuticals to Present at the 2018 BIO Investor Forum GlobeNewswire
Oct-03-18 07:30PM  Beverage Giants Buying Into The Cannabis Boom Oilprice.com
Oct-01-18 10:32AM  2 Marijuana Biotechs to Watch InvestorPlace
09:45AM  The Hottest CBD Stocks ACCESSWIRE
Sep-26-18 09:00AM  Zynerba Pharmaceuticals to Present at the Cantor Global Healthcare Conference GlobeNewswire
Sep-21-18 03:32PM  Cantor Fitzgerald's 7 Buys For 7 Biotechs Benzinga +5.74%
Sep-20-18 08:55AM  Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock? Zacks
Sep-19-18 10:30AM  CBD Stocks Set to Explode ACCESSWIRE +7.82%
08:11AM  What Makes Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) An Attractive Investment? Simply Wall St.
Aug-31-18 08:30AM  Zynerba Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference GlobeNewswire
Aug-30-18 12:42PM  Zynerba Pharmaceuticals Continues Its 3-Day Rally InvestorPlace
Aug-13-18 11:24PM  Edited Transcript of ZYNE earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-09-18 08:51AM  The Worst-Performing Marijuana Stocks in July Motley Fool
Aug-02-18 06:57AM  Zynerba: 2Q Earnings Snapshot Associated Press -10.75%
06:50AM  Zynerba Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights GlobeNewswire
Aug-01-18 08:46AM  Zynerba Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference GlobeNewswire
Jul-31-18 07:30AM  Zynerba Pharmaceuticals to Host Conference Call to Provide Second Quarter 2018 Business Update GlobeNewswire
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder. It is also developing ZYN001, a pro-drug of tetrahydrocannabinol. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Butler John P.DirectorAug 22Buy6.435,00032,1535,000Aug 22 04:39 PM
ANIDO ARMANDOChairman & Chief Exec. OfficerAug 06Buy5.9615,00089,423352,512Aug 07 04:32 PM
Sebree Terri BPresidentAug 06Buy5.793,80022,013182,546Aug 07 04:29 PM
Hanlon Suzanne M.Sec, VP & General CounselAug 06Buy5.803,80022,04843,693Aug 07 04:30 PM
Fickenscher James EChief Financial OfficerAug 06Buy5.978,51850,84220,718Aug 07 04:28 PM